ACADIA Pharmaceuticals, Inc. (ACAD)
18.14
-0.23
(-1.25%)
USD |
NASDAQ |
Nov 12, 16:00
18.12
-0.02
(-0.08%)
After-Hours: 20:00
ACADIA Pharmaceuticals Gross Profit Margin (Quarterly) : 89.75% for Sept. 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 89.75% |
| June 30, 2026 | 90.81% |
| March 31, 2026 | 90.75% |
| December 31, 2025 | 90.77% |
| September 30, 2025 | 92.23% |
| June 30, 2025 | 92.16% |
| March 31, 2025 | 91.65% |
| December 31, 2024 | 91.60% |
| September 30, 2024 | 92.47% |
| June 30, 2024 | 92.47% |
| March 31, 2024 | 88.85% |
| December 31, 2023 | 92.26% |
| September 30, 2023 | 93.09% |
| June 30, 2023 | 95.49% |
| March 31, 2023 | 98.59% |
| December 31, 2022 | 98.23% |
| September 30, 2022 | 98.37% |
| June 30, 2022 | 98.02% |
| March 31, 2022 | 97.45% |
| December 31, 2021 | 98.04% |
| September 30, 2021 | 96.89% |
| June 30, 2021 | 97.49% |
| March 31, 2021 | 97.60% |
| December 31, 2020 | 95.31% |
| September 30, 2020 | 98.01% |
| Date | Value |
|---|---|
| June 30, 2020 | 97.03% |
| March 31, 2020 | 96.48% |
| December 31, 2019 | 94.58% |
| September 30, 2019 | 97.45% |
| June 30, 2019 | 96.44% |
| March 31, 2019 | 95.31% |
| December 31, 2018 | 95.26% |
| September 30, 2018 | 93.42% |
| June 30, 2018 | 93.76% |
| March 31, 2018 | 95.59% |
| December 31, 2017 | 94.36% |
| September 30, 2017 | 94.00% |
| June 30, 2017 | 92.70% |
| March 31, 2017 | 85.20% |
| December 31, 2016 | 85.75% |
| September 30, 2016 | 83.96% |
| June 30, 2016 | -674.2% |
| March 31, 2016 | 0.00% |
| December 31, 2015 | 0.00% |
| September 30, 2015 | 0.00% |
| June 30, 2015 | 0.00% |
| March 31, 2015 | 0.00% |
| December 31, 2014 | 0.00% |
| September 30, 2014 | 0.00% |
| June 30, 2014 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Ionis Pharmaceuticals, Inc. | 95.39% |
| Arcturus Therapeutics Holdings, Inc. | 96.44% |
| ADMA Biologics, Inc. | 70.77% |
| Immunic, Inc. | -- |
| Viking Therapeutics, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 29.76% |
| Return on Assets | 22.53% |
| Return on Invested Capital | 28.34% |
| Profit Margin (Quarterly) | 15.64% |
| Operating Margin (Quarterly) | 20.95% |
| Return on Net Operating Assets | 86.77% |